Skip to content

Using Cardiac MRI to Characterise the Dynamic Changes Which Occur in the Acutely Reperfused STEMI Patient

Using Cardiac MRI to Characterise the Dynamic Changes Which Occur in the Acutely Reperfused STEMI Patient

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02791165
Enrollment
20
Registered
2016-06-06
Start date
2015-12-31
Completion date
2017-01-31
Last updated
2016-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

STEMI

Brief summary

There is an optimal day on which to perform the CMR scan which allows one to capture the information required to assess the dynamic changes in the reperfused STEMI patient. The main objective is to characterise the dynamic changes in LV function, MI size, myocardial edema, MVO, IMH, interstitial volume in the remote myocardium over the first 10 days of an acute reperfused STEMI in order to identify the optimal day for performing the CMR scan.

Detailed description

This will be a prospective observational study with serial CMR imaging only. CMR scan Each patient will receive one CMR scan performed on Day 1, Day 3, Day 5, Day 10 following the PPCI procedure on a 3T Philips scanner (see study flow below). All CMR scans will be analysed at a central CMR corelab. For Day 1, 3, 5, 7 and 10 CMRs, parameters will be collected as follows: * Left ventricle (LV) ejection fraction and indexed LV end systolic and diastolic volumes and mass using short-axis SSFP cine imaging and myocardial tagging sequences). * The AAR by T1 and T2 mapping18 as a percentage of the LV over time. * Signal intensity of T1 and T2 mapping in the MI zone, MI core and remote myocardium over time. * The incidence of intramyocardial haemorrhage (IMH)(hypo-enhancement on T2\* mapping sequence)26. * The volume of microvascular obstruction (MVO) defined as signal intensity 2 standard deviated below the mean signal intensity of the remote myocardium on the T2\* maps. Additional sequence for Day 3 and 7 CMR scans: • All the above plus MI size (measured in mass of LGE and expressed as a percentage of the LV mass).

Interventions

None listed

Sponsors

National Heart Centre Singapore
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

1. Confirmed STEMI as per PPCI procedure reports/ clinical notes 2. Proximal to mid coronary artery occlusion. 3. Ability to provide informed consent

Exclusion criteria

1. Previous myocardial infarction or coronary artery bypass graft surgery 2. Contraindication for CMR (e.g. ferromagnetic implants, claustrophobia, estimated glomerular filtration rate \<30mL/min)

Design outcomes

Primary

MeasureTime frame
All cause mortalityOne year

Countries

Singapore

Contacts

Primary ContactMung Peng
wong.mung.peng@nhcs.com.sg6704

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026